CVS vs GRDN: How CVS Health and Guardian Pharmacy Services Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and GRDN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and GRDN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.

Full CVS guide

Guardian Pharmacy Services runs closed-door pharmacies, not storefronts. Its pharmacies do not serve walk-in customers: they serve facilities, handling routine cycle fills, compliance packaging sorted by resident and dose time, urgent and after-hours deliveries, integration with facility electronic medication administration records, and the reimbursement work of billing Medicare Part D, Medicaid and commercial payors. The deliberate difference versus the incumbents is the customer type. More than two thirds of revenue comes from assisted living facilities and behavioral health facilities rather than the skilled nursing homes where Omnicare and PharMerica hold most of the share. Guardian also operates unusually for a roll-up: acquired and greenfield pharmacies are run by a local president who typically keeps a minority equity stake in that pharmacy, while corporate supplies purchasing scale, technology, billing and back office. As of March 31, 2026 that network was ~61 licensed pharmacies, ~54 of them full service, across 38 states. The company was founded in 2003 and listed on the NYSE in September 2024.

Full GRDN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
• GRDN drivers: Resident growth is running well ahead of reported revenue; A repeatable acquisition and greenfield flywheel.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For GRDN, reimbursement is the structural risk and it is not hypothetical: the IRA Part D redesign already cut prices roughly 60% on the affected portion of Guardian's branded book, and further legislative or CMS changes, plus ongoing PBM rate pressure, could compress economics again with little notice.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CVS if you believe its drivers more; GRDN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and GRDN guides.

CVS. CVS trades at a low forward earnings multiple versus the broad market, which reflects lingering caution after the 2023 to 2024 Aetna downturn rather than current results. The value angle rests on whether improving margins and ~$400 billion of revenue can support the raised guidance. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.

GRDN. The reported growth rate understates the business right now: residents and scripts both grew high single digits while revenue grew ~2%, because IRA pricing removed drug dollars that carried almost no margin. That is why gross margin widened from ~20.2% in fiscal 2025 to ~21.6% on a trailing basis, and why adjusted EBITDA guidance has been raised three times in 2026 while revenue guidance moved only once. The multiple embeds continued execution: at ~43 times trailing earnings with ~$79.8 million of trailing free cash flow, the shares are priced closer to a compounding services roll-up than to a drug distributor, and the stock has already run from a 52-week low near ~$19.30 to roughly ~$44.65.

Headline figures (approximate, 2026-06-27): CVS shows revenue (annual run-rate) ~$400 billion; FY2026 guidance at least ~$405 billion, adjusted eps (fy2026 guidance) ~$7.30 to $7.50 (Q1 2026 was ~$2.57), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier, dividend yield ~2.5% (~$2.66 annual, ~$0.665 quarterly); GRDN shows revenue (ttm) ~$1.46 billion, up ~10.3% year over year, q2 2026 revenue ~$351.8 million, up ~2% (beat the ~$340 million consensus), q2 2026 adjusted ebitda ~$29.7 million, up ~19% from ~$25.0 million, net income / eps (ttm) ~$65.9 million, ~$1.03 diluted EPS (Q2 adjusted EPS ~$0.29 vs ~$0.26 consensus).

CVS and GRDN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and GRDN exposure against your real portfolio. It is not an investment adviser.